GB0720041D0 - New Compounds - Google Patents

New Compounds

Info

Publication number
GB0720041D0
GB0720041D0 GBGB0720041.3A GB0720041A GB0720041D0 GB 0720041 D0 GB0720041 D0 GB 0720041D0 GB 0720041 A GB0720041 A GB 0720041A GB 0720041 D0 GB0720041 D0 GB 0720041D0
Authority
GB
United Kingdom
Prior art keywords
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0720041.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Priority to GBGB0720041.3A priority Critical patent/GB0720041D0/en
Publication of GB0720041D0 publication Critical patent/GB0720041D0/en
Priority to PCT/GB2008/003418 priority patent/WO2009047506A1/en
Priority to SI200831563T priority patent/SI2197880T1/sl
Priority to JP2010528478A priority patent/JP5497648B2/ja
Priority to HUE08806556A priority patent/HUE026275T2/en
Priority to DK08806556.0T priority patent/DK2197880T3/en
Priority to ES08806556.0T priority patent/ES2559685T3/es
Priority to RS20160029A priority patent/RS54518B1/sr
Priority to PT88065560T priority patent/PT2197880E/pt
Priority to CA2701865A priority patent/CA2701865C/en
Priority to US12/682,508 priority patent/US8076354B2/en
Priority to MEP-2016-3A priority patent/ME02373B/me
Priority to HRP20160002TT priority patent/HRP20160002T1/hr
Priority to EP08806556.0A priority patent/EP2197880B1/en
Priority to PL08806556T priority patent/PL2197880T3/pl
Priority to HK10111952.1A priority patent/HK1145495B/en
Priority to AU2008309418A priority patent/AU2008309418B2/en
Priority to US13/275,786 priority patent/US8859583B2/en
Priority to CY20161100043T priority patent/CY1117139T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB0720041.3A 2007-10-12 2007-10-12 New Compounds Ceased GB0720041D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB0720041.3A GB0720041D0 (en) 2007-10-12 2007-10-12 New Compounds
AU2008309418A AU2008309418B2 (en) 2007-10-12 2008-10-10 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
PT88065560T PT2197880E (pt) 2007-10-12 2008-10-10 Compostos heterocíclicos bicíclicos como inibidores da proteína tirosina cinase
US12/682,508 US8076354B2 (en) 2007-10-12 2008-10-10 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
JP2010528478A JP5497648B2 (ja) 2007-10-12 2008-10-10 タンパク質チロシンキナーゼインヒビターとしての二環式ヘテロ環式化合物
HUE08806556A HUE026275T2 (en) 2007-10-12 2008-10-10 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
DK08806556.0T DK2197880T3 (en) 2007-10-12 2008-10-10 Bicyclic heterocyclic compounds AS protein tyrosine
ES08806556.0T ES2559685T3 (es) 2007-10-12 2008-10-10 Compuestos bicíclicos heterocíclicos como inhibidores de la proteína tirosina quinasa
RS20160029A RS54518B1 (sr) 2007-10-12 2008-10-10 Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze
PCT/GB2008/003418 WO2009047506A1 (en) 2007-10-12 2008-10-10 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
CA2701865A CA2701865C (en) 2007-10-12 2008-10-10 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
SI200831563T SI2197880T1 (sl) 2007-10-12 2008-10-10 Biciklične heterociklične spojine kot inhibitorji protein tirozin kinaze
MEP-2016-3A ME02373B (me) 2007-10-12 2008-10-10 Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze
HRP20160002TT HRP20160002T1 (hr) 2007-10-12 2008-10-10 Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze
EP08806556.0A EP2197880B1 (en) 2007-10-12 2008-10-10 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
PL08806556T PL2197880T3 (pl) 2007-10-12 2008-10-10 Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej
HK10111952.1A HK1145495B (en) 2007-10-12 2008-10-10 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
US13/275,786 US8859583B2 (en) 2007-10-12 2011-10-18 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
CY20161100043T CY1117139T1 (el) 2007-10-12 2016-01-18 Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνης κινασης τυροσινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0720041.3A GB0720041D0 (en) 2007-10-12 2007-10-12 New Compounds

Publications (1)

Publication Number Publication Date
GB0720041D0 true GB0720041D0 (en) 2007-11-21

Family

ID=38788133

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0720041.3A Ceased GB0720041D0 (en) 2007-10-12 2007-10-12 New Compounds

Country Status (17)

Country Link
US (2) US8076354B2 (enExample)
EP (1) EP2197880B1 (enExample)
JP (1) JP5497648B2 (enExample)
AU (1) AU2008309418B2 (enExample)
CA (1) CA2701865C (enExample)
CY (1) CY1117139T1 (enExample)
DK (1) DK2197880T3 (enExample)
ES (1) ES2559685T3 (enExample)
GB (1) GB0720041D0 (enExample)
HR (1) HRP20160002T1 (enExample)
HU (1) HUE026275T2 (enExample)
ME (1) ME02373B (enExample)
PL (1) PL2197880T3 (enExample)
PT (1) PT2197880E (enExample)
RS (1) RS54518B1 (enExample)
SI (1) SI2197880T1 (enExample)
WO (1) WO2009047506A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007337886C1 (en) * 2006-12-22 2014-10-16 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
CN101679409B (zh) * 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
FR3000746A1 (fr) 2013-01-04 2014-07-11 Centre Nat Rech Scient Peptide pour son utilisation dans le traitement des neuronopathies motrices
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016152907A1 (ja) 2015-03-25 2016-09-29 国立研究開発法人国立がん研究センター 胆管癌治療剤
WO2017049498A1 (zh) * 2015-09-23 2017-03-30 前湾医药科技（深圳）有限公司 一种咪唑并吡啶类化合物与在制备pi3k抑制剂中的应用
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
RU2018117889A (ru) 2015-10-16 2019-11-20 Эббви Инк. СПОСОБЫ ПОЛУЧЕНИЯ (3S,4R)-3-ЭТИЛ-4-(3H-ИМИДАЗО[1,2-a]ПИРРОЛО[2,3-e]-ПИРАЗИН-8-ИЛ)-N-(2,2,2-ТРИФТОРЭТИЛ)ПИРРОЛИДИН-1-КАРБОКСАМИДА И ЕГО ТВЕРДОФАЗНЫХ ФОРМ
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN108367000A (zh) 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR102782563B1 (ko) * 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
AU2018354785A1 (en) * 2017-10-24 2020-04-23 Bayer Aktiengesellschaft Substituted imidazopyridine amides and use thereof
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
PL3788047T3 (pl) 2018-05-04 2025-04-14 Incyte Corporation Stałe postacie inhibitora fgfr i sposoby ich otrzymywania
KR20210018264A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 염
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR102753831B1 (ko) 2019-07-26 2025-01-14 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Fgfr 및 vegfr 이중 억제제로서의 피리딘 유도체
WO2021067374A1 (en) * 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022161408A1 (zh) * 2021-01-26 2022-08-04 南京明德新药研发有限公司 甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2025140656A1 (en) * 2023-12-30 2025-07-03 Fujian Haixi Pharmaceuticals Co., Ltd. Heteroaryl compounds as multi-target protein kinase inhibitors
WO2025140655A1 (en) * 2023-12-30 2025-07-03 Fujian Haixi Pharmaceuticals Co., Ltd. Heteroaryl compounds as multi-target protein kinase inhibitors

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5554630A (en) 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
CN1046725C (zh) 1994-06-20 1999-11-24 武田药品工业株式会社 稠合的咪唑化合物,它们的制备和应用
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
ES2294800T3 (es) 1996-07-24 2008-04-01 Bristol-Myers Squibb Pharma Company Azolo triazinas y pirimidinas.
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
IL137019A0 (en) 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
EP1109555A4 (en) 1998-08-31 2001-11-21 Merck & Co Inc Novel angiogenesis inhibitors
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003503351A (ja) * 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
US6316444B1 (en) 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
GB9927687D0 (en) 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
US7105550B2 (en) 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
MXPA02007603A (es) 2000-03-09 2003-02-24 Aventis Pharma Gmbh Usos terapeuticos de mediadores ppar.
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
AU2001277032A1 (en) 2000-08-04 2002-02-18 Warner Lambert Company 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7 ones
WO2002034748A1 (fr) 2000-10-24 2002-05-02 Sankyo Company, Limited Derives d'imidazopyridine
GB0027561D0 (en) 2000-11-10 2000-12-27 Merck Sharp & Dohme Therapeutic agents
EP1341768A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
CN100415744C (zh) 2001-02-20 2008-09-03 阿斯特拉曾尼卡有限公司 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
DE10117183A1 (de) 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
WO2002088107A1 (fr) 2001-04-26 2002-11-07 Eisai Co., Ltd. Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2003091256A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
DE60318198T2 (de) 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
AUPS251402A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Kinase inhibitors
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
GB0212049D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
JP4602076B2 (ja) 2002-06-04 2010-12-22 ネオジェネシス ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５ａ］ピリミジン化合物
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
EP1539756B1 (en) 2002-09-19 2007-11-14 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
WO2004035579A1 (ja) 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited イミダゾピリジン誘導体、その製造法および用途
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
WO2004052286A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
US7826979B2 (en) 2003-02-14 2010-11-02 Vertex Pharmaceuticals Incorporated Method of modeling complex formation between a query ligan and a target molecule
US7476670B2 (en) 2003-02-18 2009-01-13 Aventis Pharma S.A. Purine derivatives, method for preparing, pharmaceutical compositions and novel use
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
JP2007502822A (ja) 2003-08-21 2007-02-15 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｃ−Ｋｉｔ阻害剤としてのＮ３−置換イミダゾピリジン誘導体
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
WO2005021531A1 (en) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors
NZ545694A (en) 2003-12-03 2010-04-30 Ym Bioscience Australia Pty Lt Azole-based kinase inhibitors
US7560568B2 (en) 2004-01-28 2009-07-14 Smithkline Beecham Corporation Thiazole compounds
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
WO2005108399A1 (ja) 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US7718801B2 (en) 2004-08-31 2010-05-18 Banyu Pharmaceutical Co., Ltd. Substituted imidazole derivative
KR20070057965A (ko) 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
EP1831206B1 (en) 2004-12-01 2011-08-24 OSI Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
US20080167314A1 (en) 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
EP1853590A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
JP2008534689A (ja) 2005-04-05 2008-08-28 ファーマコペイア， インコーポレイテッド 免疫抑制のためのプリン及びイミダゾピリジン誘導体
FR2884821B1 (fr) 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
BRPI0616722A2 (pt) 2005-09-30 2012-12-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
US8119643B2 (en) 2006-03-20 2012-02-21 Synta Pharmaceuticals Corp. Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
CA2646886A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
ITVA20060041A1 (it) 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1882475A1 (en) 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CN101679409B (zh) 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
AU2007337886C1 (en) * 2006-12-22 2014-10-16 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
HRP20130660T1 (en) 2007-04-03 2013-08-31 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
CN101765585B (zh) 2007-06-12 2017-03-15 尔察祯有限公司 抗菌剂
EP2170882A1 (en) 2007-06-26 2010-04-07 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds

Also Published As

Publication number Publication date
US8076354B2 (en) 2011-12-13
SI2197880T1 (sl) 2016-04-29
PL2197880T3 (pl) 2016-07-29
EP2197880A1 (en) 2010-06-23
DK2197880T3 (en) 2016-01-25
AU2008309418A1 (en) 2009-04-16
HK1145495A1 (zh) 2011-04-21
ES2559685T3 (es) 2016-02-15
WO2009047506A1 (en) 2009-04-16
ME02373B (me) 2016-06-20
CY1117139T1 (el) 2017-04-05
US20100331296A1 (en) 2010-12-30
HRP20160002T1 (hr) 2016-03-11
EP2197880B1 (en) 2015-12-23
US8859583B2 (en) 2014-10-14
JP5497648B2 (ja) 2014-05-21
PT2197880E (pt) 2016-02-23
US20120035153A1 (en) 2012-02-09
CA2701865C (en) 2016-01-26
JP2011500544A (ja) 2011-01-06
CA2701865A1 (en) 2009-04-16
AU2008309418B2 (en) 2014-04-17
RS54518B1 (sr) 2016-06-30
HUE026275T2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
GB0720038D0 (en) New compounds
GB0720041D0 (en) New Compounds
GB0706793D0 (en) Compounds
GB0704407D0 (en) Compounds
GB0704394D0 (en) Compounds
GB0722769D0 (en) New compounds
GB0701273D0 (en) New compounds
GB0705672D0 (en) Compounds
GB0706173D0 (en) Compounds
HU0700395D0 (en) New compounds
GB0706168D0 (en) Compounds
GB0707034D0 (en) Compounds
GB0706165D0 (en) Compounds
GB0706188D0 (en) Compounds
GB0706189D0 (en) Compounds
GB0706167D0 (en) Compounds
GB0706174D0 (en) Compounds
GB0706187D0 (en) Compounds
GB0706170D0 (en) Compounds
GB0704939D0 (en) Compounds
GB0703756D0 (en) Compounds
GB0701955D0 (en) Compounds
GB0701985D0 (en) Compounds
GB0701780D0 (en) New compounds
GB0719998D0 (en) New compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)